Unconjugated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Monomer, MALS verified)

ユーザーレビュー
製品番号/仕様
価格
数量
HLD-H52E6-25ug
$125.00
HLD-H52E6-200ug
$700.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Synonyms

    HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK)

  • Source

    Unconjugated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (HLD-H52E6) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Thr 305 (HLA-A*11:01) & Ile 21 - Met 119 (B2M) & VVVGADGVGK peptide (Accession # Q5S3G3-1 (HLA-A*11:01) & P61769 (B2M) & VVVGADGVGK).

    Predicted N-terminus: Gly 25 & Ile 21

    Request for sequence
  • Molecular Characterization

    Unconjugated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein is produced by co-expression of HLA and B2M loaded with KRASG12D peptide.

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™), and it is not biotinylated.

    The protein has a calculated MW of 36.0 kDa and 11.7 kDa. The protein migrates as 38-41 kDa and 11 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SDS-PAGE

    HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) SDS-PAGE

    Unconjugated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) SEC-MALS

    The purity of Unconjugated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Cat. No. HLD-H52E6) is more than 95% and the molecular weight of this protein is around 45-65 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) ELISA

    Immobilized Unconjugated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Cat. No. HLD-H52E6) at 1 μg/mL (100 μL/well) can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-4 ng/mL (QC tested).

    Protocol
  •  HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) ELISA

    Immobilized Unconjugated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Cat. No. HLD-H52E6) at 1 μg/mL (100 μL/well) can bind Anti-B2M Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) SPR

    Unconjugated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Cat. No. HLD-H52E6) captured on CM5 Chip via Anti-B2M antibody can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with an affinity constant of 0.168 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

ユーザーレビュー
コメントを投稿

バックグランド

The Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network represents a major target for therapeutic intervention. The Human HLA-A*1101 KRASG12D (VVVGADGVGK) complex protein is a complex of HLA-A*1101 of the MHC Class I, B2M, and VVVGADGVGK peptide of the KRASG12D.

最新の進展

 
お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8